<?xml version="1.0" encoding="UTF-8"?>
<p>In that context, “classical” anti-inflammatory drugs are indeed currently being tested against COVID-19 [e.g., methylprednisolone, budesonide, hydrocortisone, azithromycin, and non-steroïdal anti-inflammatory drugs (NSAIDs)]. In addition, more specific agents are also being investigated, targeting either IL-β (anakinra, 13 hits), IL-6 signaling (Siltuximab/3 hits, Tocilizumab/42 hits, Sarilumab/13 hits), or CD24 (CD24Fc) with the main objective to modulate the “cytokine storm.”</p>
